

# IG Screening Guidance for Healthcare Providers

For persons 12 months to 40 years of age, hepatitis A vaccination is recommended for prophylaxis against hepatitis A exposure. The use of IG is recommended or generally preferred in the following persons exposed to hepatitis A:

## IG recommended:

- Infants less than 12 months (due to data showing reduced response to hepatitis A vaccination)
- Persons with a contraindication to hepatitis A vaccine (to prevent an adverse event)
- Immunocompromised persons (due the expectation that overall response to vaccination will be reduced)
- Persons with chronic liver disease (due to lack of efficacy data when hepatitis A vaccine is used and potential severity of hepatitis A disease)

## IG preferred, but if IG is contraindicated may give hepatitis A vaccine:

- Persons 40 years and older (preferred due to lack of efficacy data when hepatitis A vaccine is used)

### Patients should be asked the following questions prior to receiving IG:

*If the answer to any of these questions is yes, IG is contraindicated.*

<b>1. Do you have a known IgA deficiency?</b> <i>People who are unsure of this most likely do not have IgA deficiency as it is a chronic condition and would need ongoing medical care</i>	Yes	No
<b>2. Have you received an MMR, Varicella (chickenpox), or rotavirus vaccine in the last 3 weeks?</b> <i>Instruct people who have had MMR or varicella within the past 2 weeks that they will need to be revaccinated, and they will need to wait at least 3 months before doing so.</i>	NA	NA
<b>3. Is this an infant who could receive or has received rotavirus vaccine?</b> <i>Explain to parents of infants who have recently received rotavirus vaccination that the protection from the vaccine may be lowered because of IG administration. There is no recommendation for rotavirus revaccination. ACIP recommends that if the six-week deferral for rotavirus vaccination causes the a first dose of rotavirus to be scheduled on or after 13 weeks old or the final dose after age 32 weeks the provider should disregard the full deferral period and proceed to vaccinate.</i>	NA	NA
<b>4. Have you ever had a reaction to a prior dose of IG?</b> <i>Persons who describe a systemic reaction, i.e., urticaria, wheezing, or angioedema should not receive IG.</i>	Yes	No
<b>5. Do you have a clotting disorder?</b> <i>This includes thrombocytopenia. The concern is that a deep IM injection may induce significant bleeding into the tissue.</i>	Yes	No
<b>6. Have you ever received the hepatitis A vaccine?</b> If yes, when did you receive the vaccine? ___/___/___ <ul style="list-style-type: none"> <li>• If the patient can only recall the month and year IG is not necessary. If they are unsure, give IG.</li> <li>• If vaccination has occurred within the last 4 weeks, give IG for the following: age 40 years or older, chronic medical conditions including chronic liver disease, immunocompromised.</li> <li>• IG is not necessary if they have not completed the hepatitis A vaccination series – one dose will provide protection. They should be advised to complete the series. If available, and if it has been at least 6 months since the first dose, give hepatitis A vaccine at this time.</li> </ul>	Yes	No
<b>7. Have you ever been diagnosed with hepatitis A?</b> <i>Give IG if the person has any doubt.</i>	Yes	No

#### Sources:

AAP. Hepatitis A in *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. 2006:329, 334-335.

CDC. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2006;55(No. RR-15) [<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm>]

CDC. Prevention of Rotavirus Gastroenteritis Among Infants and Children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2006;55(No. RR-12) [<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5512a1.htm>]

CDC. Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2006;55(No. RR-7) [<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm>]

CDC. Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. October 19, 2007 / 56(41):1080-1084. [<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5641a3.htm>]

Talecris Biotherapeutics. Package Insert for *Immune Globulin (Human) GamaSTAN*, June 2007



Vaccine-Preventable Disease Surveillance  
P.O. Box 64975  
St. Paul, MN 55164-0975  
651-201-5414 or 877-676-5414  
[www.health.state.mn.us/immunize](http://www.health.state.mn.us/immunize)